Trial Profile
Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release In Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Elcelyx Therapeutics
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 22 Nov 2016 Status changed from active, no longer recruiting to completed.
- 10 Nov 2016 Primary endpoint has been met. (Change in HbA1c (%) at 16 Weeks)